Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219576 · ClinicalTrials.gov registry record · Phase 1
Retifanlimab and Ruxolitinib In Solid Malignancies
A Phase 1 study of Renal Cell Carcinoma and Non-Small-Cell Lung Carcinoma, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07219576 is a Phase 1 study of Renal Cell Carcinoma and Non-Small-Cell Lung Carcinoma that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 40 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07219576, a Phase 1 study of Renal Cell Carcinoma and Non-Small-Cell Lung Carcinoma, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma. The main question it aims to answer is: What is the maximum dose of ruxolitinib that can be used safely in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma, and will it work? Participants will: Take drug ruxolitinib twice a day and keep a diary of when they take ruxolitinib at home; visit the clinic for infusions of retifanlimab every 4 weeks; visit the clinic for checkups and tests.
Conditions Studied
Interventions
- DRUG Retifanlimab
- DRUG Ruxolitinib
Study Locations (1)
California
- University of California, San Diego Moores Cancer Center - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-01-08 |
| Est. Completion | 2029-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07219576
The ClinicalTrials.gov registry entry for NCT07219576 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (84% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Retifanlimab is the first listed.
NCT07219576 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07219576 about?
NCT07219576 is a clinical study titled "Retifanlimab and Ruxolitinib In Solid Malignancies". The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma. The main question it aims to answer is: What is the maximum dose of ruxolitinib that can be used s...
What is the current status of trial NCT07219576?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-01-08. Estimated completion is 2029-12.
What conditions does trial NCT07219576 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Non-Small-Cell Lung Carcinoma.
What interventions are being tested in trial NCT07219576?
The interventions under investigation include: Retifanlimab (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT07219576?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219576 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RECRUITING · Phase 1
-
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.